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Ninety-six patients with the diagnosis of adult T-cell leukemia/lymphoma (ATLL) were
identified incountriesoutside JapanandtheCaribbean Basin. Seventy-fourofthesepatientswere
initially diagnosed in the United States; 25 of 52 patients whose places ofbirth were known had
been born in the United States. The detection of 14 patients born in the southeastern United
States, all black, indicates a group deserving particular attention for studies of human T-cell
lymphotropic virus type I (HTLV-I), a suspected etiologic agent in most cases of ATLL.
Although geographic clustering of ATLL in areas endemic for HTLV-I, particularly southwest
Japan and the Caribbean Basin, is a dramatic feature of this disease, a review of the literature
indicates that HTLV-I-associated ATLL probably occurs sporadically in a much wider distri-
bution, the disease being diagnosed in native-born African, Chinese, European, and Latin
American patients. A registry for ATLL cases is suggested, to assist in the identific ii.on of risk
factors for this disease and, at the same time, improve case definitions and early diagnosis.
INTRODUCTION
Adult T-cell leukemia/lymphoma (ATLL), a hematologic malignancy associated
with the first isolated human retrovirus, human T-cell lymphotropic virus type I
(HTLV-I), is an aggressive malignancy most frequently found in southwest Japan,
particularly in the Goto Islands where the estimated incidence rate is 24.2/100,000
[1], and also on certain Caribbean islands such as Jamaica, where approximately half
of the non-Hodgkin's lymphoma cases are ATLL [2]. The geographic clustering of
HTLV-I and ATLL in the same restricted areas is particularly striking and supports
the etiologic relationship between the virus and the malignancy [1,3].
HTLV-I is extremely cell-associated and, therefore, is not readily transmitted.
Current evidence suggests at least four likely routes of transmission for this virus.
Transmission from mother tochild has been well documented [4-6]. Infection in utero
and peripartum are both possible, but thedemonstration ofHTLV-I in breast milkand
data from observational studies in Japan suggest that breast feeding is the major
mother-child transmission mechanism. Theconcern about transmission via breast milk
has led Japanese workers to advise HTLV-I-seropositive mothers not to nurse their
children [7], but this suggestion would not be practical in poorer countries, where
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TABLE 1
Diagnostic Criteria for Adult T-Cell
Leukemia/Lymphoma (ATLL)
1. Malignant mature T-cells
2. Peripheral blood involvement
3. Polylobulated lymphocytes
4. Skin manifestations
5. Hypercalcemia/bone lesions
6. Lymphadenopathy/hepatosplenomegaly
infants would clearly be at higher risk of death from malnutrition if they were not
breast-fed. Transfusion of HTLV-I-positive blood is another apparent route of
infection [8,9]. Epidemiologic studies have suggested that transfusion of HTLV-
I-infected blood may be responsible for the subsequent development of
HTLV-I-associated myelopathy or tropical spastic paraparesis [10], another disease
suggested as being due to HTLV-I [11-14]. There have been no reports, however, of
ATLL linked to transfusion. Regarding other routes oftransmission, there is consider-
able evidence for transmission ofHTLV-I by sexual activity, particularly from male to
female [15], and via needle sharing among intravenous drug abusers [16]. The
implications of these findings are quite important in view of the great potential for
males to transmit HTLV-I to their female sexual partners, whocould then readily pass
thevirus to theiroffspring. Mosquitoes areunlikely tobevectors for HTLV-I infection,
as shown by both laboratory [Reeves W: personal communication] and epidemiologic
[1,3] studies.
While ATLL has been reported most often in people of Japanese and African
descent, this disease has a wide geographic distribution and occurs in people of
virtually all racial/ethnic groups. The precise delineation of the pattern of ATLL,
however, is obscured by several factors. First, ATLL is not a homogeneous histopatho-
logic entity [17-19], a spectrum of histologic subtypes being found both in endemic
[2,19] and non-endemic [17,20] regions. As of this date, no particular histologic
subtype has been shown to correlate with any particular clinical or demographic
feature of ATLL. When there is skin involvement, the differentiation between ATLL
and mycosis fungoides can be particularly difficult, even for hematopathologists
possessing considerable experience with these diseases. Therefore, the diagnosis of
ATLL rests on a constellation ofclinical and pathologic features (Table 1). The most
consistent pathologic feature is the presence of circulating polylobulated lymphoid
cells. While the presence ofmalignant mature T cells is a hallmark ofthe disease, this
criterion cannot always be documented, since not all hospitals routinely type tumors
from patients with hematologic malignancies. The prominence of the other signs in
various series will be discussed later.
A second controversial area is the role ofHTLV-I assays in the diagnosis ofATLL.
The presence of HTLV-I antibody in a patient with clinical signs and symptoms of
ATLL is suggestive but not conclusive, since many individuals, both cancer patients
and thosewith noapparent disease, can haveantibodies to HTLV-I totallyunrelated to
any pathogenic process; however, the finding of HTLV-I provirus integrated into the
tumor cells of a patient with the clinical features listed here makes the diagnosis of
ATLL unequivocal. Oneproblem faced byinvestigators studying ATLL is that there is
no complete agreement as to how to classify HTLV-I-negative patients. Currently,
216HTLV-I AND ATLL OUTSIDE JAPAN AND THE CARIBBEAN BASIN
since seronegative patients have been identified in Japan [19] and Jamaica [2] with
clinicopathologic features indistinguishable from seropositive ATLL, most investiga-
tors do not require evidence of HTLV-I infection in making the diagnosis of ATLL.
This issue will need to be re-evaluated as more cases are collected and more laboratory
assays are applied to disease classification.
At theNational Cancer Institute, wehavebegun tocollect cases diagnosed as ATLL
from areas outside Japan and the Caribbean in order to improve the case definition as
well as to address the following questions:
1. Can we identify any particular risk factors, other than HTLV-I, consistently
distinguishing ATLL cases from the general population?
2. Will our identification of ATLL cases lead to finding "clusters" of HTLV-I
infection that have not previously been recognized?
3. Are there any features that distinguish HTLV-I-positive ATLL (defined by
viral genome detection rather than antibody positivity) from HTLV-I-negative
cases?
4. Can we define any serologic profiles useful in predicting disease outcome
comparable to the use of Epstein-Barr virus (EBV) serology in Burkitt's lymphoma
and nasopharyngeal carcinoma?
5. By reviewing the clinical histories ofU.S. cases, can wedevelop mechanisms to
alert clinicians to early detection and more effective treatment ofthis disease?
MATERIALS AND METHODS
The source ofcases for this series included patients whose sera have been sent to our
laboratory for HTLV-I antibody testing (37 cases), cases referred to oneofus (EJ) for
pathologic confirmation (22 cases), patients that our group has personally investigated
(12 cases), and cases gleaned from the literature (three U.S. patients and all non-U.S.
patients).
RESULTS
ATLL cases diagnosed in the United States had many characteristics of cases
identified in the Caribbean Basin (Table 2); the median age was 55.5 years for males
and 50.5 years for females, most patients were black, and the disease usually pursued
an aggressive course. Malespredominated in theU.S.-born cases (16 males, 9 females)
but not in those born outside the U.S. (11 males, 16 females).
Information available thus far regarding place of birth (Table 3) confirms the
suggestion by Blayney et al. [21] that the southeastern U.S. is an important focus of
ATLL, with 14 of the 25 native U.S. cases being born in the Carolinas, Georgia,
Alabama, and Florida. Of these 14 patients, all were black. The identification of a
significant proportion of cases born in the Caribbean region and Japan is not
surprising, since it is well known that being born in an ATLL-endemic area is a major
risk factor for the disease. Furthermore, the development ofATLL in patients born in
Latin America is consistent with our concurrent studies in Panama and Colombia,
where there are several reported cases of ATLL in native-born Latin Americans
[20,22].
The prognosis of ATLL is generally unfavorable regardless of the type of therapy
employed. In our series, the median survival time was two months. One patient with an
exceptionally long remission, a woman born in Tokyo, was first diagnosed with ATLL
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TABLE 2
Demographic Features of ATLL Patients Diagnosed in the U.S.'
Sex
Age
Median (range)
Racial/Ethnic Origin
Black
White
Hispanic/Mestizo
Japanese
Sex
Age
Median (range)
Racial/Ethnic Origin
Black
White
Hispanic/Mestizo
Japanese
Male Female
U.S.-Born Cases
16
55.5 (26-76)
12
3
0
1
Non-U.S.-Born Cases
11
43 (30-58)
7
2
2
0
9
50.5 (26-71)
8
0
0
16
44 (23-66)
11
0
3
2
'Place ofbirth not identified in 22 patients
TABLE 3
Place of Birth of 74 ATLL Cases Diagnosed in the United States
Cases PlaceofBirth No. ofCases
U.S.-born (25)'
Foreign-born (27)
South Carolina
Alabama
Florida
Georgia
Hawaii
New York
North Carolina
Tennessee
Alaska
District ofColumbia
Louisiana
Massachusetts
Texas
Jamaica
Haiti
Colombia
Japan
Trinidad and Tobago
Brazil
Chile
Curacao
Dominican Republic
Ecuador
Grenada
Honduras
Israel
St. Lucia
"Place ofbirth not identified in 22 patients
6
2
2
2
2
2
2
2
1
1
8
4
2
2
2
1
1
1
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TABLE 4
Clinical Features of ATLL
U.S.A. and
Overall [18] Japan [19] Jamaica [32] Panama [18,20]
No. (%) No. (%) No. (%) No. (%)
Clinical
Leukemia 159/263(60) 115/197(58) 25/42(60) 19/24(79)
Hypercalcemia 97/255(38) 57/192(30) 23/42(55) 17/21(81)
Bone marrow infiltration 129/259(50) 104/197(53) 19/42(45) 6/20(30)
Generalized lymphadenopathy 173/261(66) 117/197(59) 39/42(93) 17/22(77)
Skin involvement 89/263(34) 67/197(34) 10/42(24) 12/24(50)
Hepatosplenomegaly 84/261(32) 56/197(28) 16/42(38) 12/22(55)
Lytic bone lesions 4/24(17) 0/4(0) N.R. 4/20(20)
N.R.: not reported
in 1983 at the ageof40, and afterchemotherapy with six monthsofcyclophosphamide,
adriamycin, methotrexate, vincristine, VP-16, and prednisone, she achieved a remis-
sion which persisted for four years until disseminated disease appeared in December
1987.
The clinical features of the patients in our U.S. series, comparable to the data
reported by Clark et al. [18], are generally similar to those in other geographic locales.
While we find an increased incidence of hypercalcemia and lytic bone lesions in the
U.S. over that reported in Japan and the Caribbean (Table 4), this finding may be due
to an emphasis on these features in our early case reports [23], since a lower frequency
ofhypercalcemia has been observed in our more recent patients.
Serologic studies for HTLV-I were performed in 69 of our 74 patients; 68 of these
sera were reported to beantibody-positive by a screening ELISA test, butconfirmation
by our more specific assays was performed on only 44 of these sera. Virologic studies
were performed on cell cultures derived from the malignant T lymphocytes ofseven of
these patients, all demonstrating the presence of HTLV-I genome in the tumor cells.
We have thus far identified 22 cases of ATLL diagnosed outside Japan, the
Caribbean islands, and the United States [20,22,24-29]. While 11 were born in the
Caribbean Basin [24,25], other reports indicate that ATLL can occur in lifetime
residents of Africa [27], Asia [28,29], Europe [26], and Latin America [20,22].
Serologic and virologic studies in some of the patients born outside Japan and the
Caribbean islands have included documentation ofHTLV-I viral genome in the tumor
cells [26,27] or cell lines derived from tumor cells [24], one patient with viral
genome-positive tumor cells having no HTLV-I antibody detectable in the serum
[26].
DISCUSSION
ATLL was first identified as a clinical-pathologic entity in 1977 by Uchiyama et al.
[30], who observed a series of cases with the classical features of leukemia, hypercal-
cemia, lymphadenopathy, and skin lesions in Tokyo. The subsequent association of
HTLV-I with classical cases in the endemic areas of Japan and the broadening
spectrum of clinical manifestations accepted as part of ATLL have blurred the
definition of this disease and have led to difficulties in the development of epidemio-
logic studies, particularly in areas where both case identification and detection of
antibodies to HTLV-I are infrequent.
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In an attempt to clarify the epidemiology of ATLL, we have thus far identified 74
cases diagnosed as ATLL in the U.S. and 22 cases diagnosed in othercountries outside
Japan and the Caribbean Basin. Because information on patients not seen at the NIH
is incomplete, and the registration is not population-based, our results may be biased.
Nevertheless, several features of importance have emerged, identifying areas for
future research.
The large percentage of patients born in the southeastern United States provides
additional support to the observation of Blayney et al. [21] that this area deserves
further study in regard to the distribution of HTLV-I, particularly in the black
population. Two other interesting findings in this series of patients are the higher
frequency ofhypercalcemia in comparison to series from Japan and the Caribbean and
the important, although unusual, observation thataggressivechemotherapycan lead to
prolonged unmaintained remission ofgreater than four years. Regarding the hypercal-
cemia, this finding could represent reporting bias, possibly due in part to the emphasis
on hypercalcemia in previous clinical reports [18,23].
In regard to the identification of risk factors other than HTLV-I, additional cases
are needed before the leads generated by studies in Japan and the Caribbean Basin are
pursued. Lower socioeconomic status has been reported to be important in Japan and
the Caribbean but has not been rigorously examined in the U.S. Certainly infection
with HTLV-I and being born in an area with a higher incidence ofATLL appear to be
significant risk factors in the U.S. Finally, the role ofgenetics in the etiology ofATLL
remains uncertain. The high prevalence in two genetically diverse groups such as
Japanese and Caribbean blacks suggests a relatively unimportant role for genetic
susceptibility, but it would be premature at this time to rule out completely genetic
susceptibility asonecontributing factor, particularly inview ofa reportby Usuku et al.
suggesting an association between human leukocyteantigen (HLA) typeand ATLL in
Japan [31].
Further progress in studies on the etiology and control ofATLL will depend in large
part on a more precise case definition of this disease. At the present time, only those
cases with typical clinicopathologic features and HTLV-I provirus detected in the
malignant tumor cells are accepted universally as being ATLL. Serologic identifica-
tion of HTLV-I antibody is a useful screening test for this disease, but seropositive
patients may not have virus integrated into the tumor cells and, conversely, viral
integration can occur without detectable antibody. Evaluation of a broad base of
malignant lymphoproliferative diseases is necessary to define the entire clinical
spectrum ofATLL. In view ofthe need to clarify the definition ofATLL as well as its
value as a sentinel to pockets of HTLV-I infection, the development of a registry of
ATLL cases could be ofgreat value.'
'Physicians are encouraged to report any suspected cases ofATLL to Dr. Levine at the National Cancer
Institute (301-496-4375). Serologic andpathologic evaluations will beperformed at NIH expense.
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